Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

20 year followup on high-dose chemo with HSCT in high-risk breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.10.18
Views: 472

Dr Tessa Steenbruggen - Netherlands Cancer Institute, Amsterdam, Netherlands

Dr Steenbruggen speaks with ecancer at ESMO 2018 in Munich about the results from a 20 year followup of survival data from a trial of 885 women treated with high-dose chemotherapy and stem cell transplant between 1993-1999.

She describes how survival and safety data, linked to cancer registries, shows no overall improvement compared to the 5 year results.

Women with 10 or more positive lymph nodes faired slightly better than others, the benefit in patients with 10 or more axillary lymph nodes was found to be statistically significant while the overall survival in all patients was not statistically significant.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation